Other studies have shown promise in IFN-γ blockade to treat severe CRS, though these are largely limited to the pediatric B-cell acute lymphoblastic leukemia population, with only one adult case report published to the best of our knowledge (11–13). This evidence concerns the gene IFNG and congenital rubella syndrome.